Background. Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against C. difficile ...

The procedure involves transplanting a stool sample from a healthy donor to treat C. difficile. One-quarter of patients who contract a C. difficile infection will have a recurrence, and those who do ...

Fecal microbe transplants from healthy donors can treat patients with recurrent Clostridium difficile infections. However, after tens of thousands transplants, little was known about which donor ...

Three recent studies tackled strategies aimed at preventing recurrent Clostridium difficile infection (RCDI). Adding a single dose of bezlotoxumab—a monoclonal antibody that neutralized C difficile ...

The National Institute for Health and Care Excellence (NICE) has recommended faecal microbiota transplant (FMT) as a treatment option for those with recurrent Clostridium difficile (C diff) infections ...

Fecal microbe transplants from healthy donors can treat patients with recurrent Clostridium difficile infections. However, after tens of thousands transplants, little was known about which donor ...

Gastric suppression medication use increases risk of recurrent Clostridium difficile infection, according to a study conducted by Rochester, Minn.-based researchers and published in JAMA Internal ...

WCM-Q Coordinated E-Book 'Fecal Microbiota Transplants' Surpasses 100,000 Views In A Month. The Peninsula Doha, Qatar: An ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

As expected, Seres Therapeutics Inc. gained U.S. FDA approval of the BLA for the oral microbiome therapeutic Vowst, formerly known as SER-109, for prevention of recurrent Clostridium difficile ...